|
|
|
|
| The 2004 AAN/AES Treatment Guidelines
|
|
|
|
|
|
|
|
|
|
The 2004 AAN/AES Treatment Guidelines Support the Use of LAMICTAL
Evidence-based guidelines recommend LAMICTAL for the following approved indications1
| INDICATION FOR USE
|
AAN/AES
RECOMMENDATION
|
| Adjunctive therapy for pediatric patients ≥2 years with partial seizures*
|
|
| Adjunctive therapy for generalized seizures of LGS (atonic, tonic, major myoclonic, and tonic-clonic)†
|
|
| Adjunctive therapy for adults with partial seizures‡
|
|
| Adjunctive therapy for pediatric and adult patients with primary generalized tonic-clonic seizures
|
These guidelines preceded publication of the study supporting approval of the PGTC seizure indication
|
| Conversion to monotherapy for adults with partial seizures taking carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED§
|
|
*Described as "pediatric partial"in the AAN/AES guidelines.
†Described as "symptomatic generalized" in the AAN/AES guidelines.
‡Described as "partial adjunctive adult" in the AAN/AES guidelines.
§Described as "partial monotherapy" in the AAN/AES guidelines.
RESULTS FROM: FRENCH ET AL. Efficacy and tolerability of the new antiepileptic drugs II. Neurology. 2004;62:1261-1273.
Guideline Methodology: A structured literature search was conducted, and the data were rated according to stringent criteria set by the committee. Recommendations for use were based on the weight and quality of the evidence demonstrating efficacy and tolerability of the newer AEDs for each seizure type/population assessed.
This project was sponsored by unrestricted grants from Abbott Laboratories, GlaxoSmithKline, Novartis Pharmaceuticals, and UCB Pharma.
Safety and effectiveness have not been established 1) as initial monotherapy, 2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate, or 3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs.
|
|
|
|
|
|
|
|
| EFFICACY AND TOLERABILITY
|
|
|
|
|
|
|
|
| Initiate with ease—convert with confidence. Learn more.
|
|
|
|
|
|
|
|
| IMPORTANT SAFETY INFORMATION
|
|
|
|
|
|
|
| Important Safety Information About LAMICTAL and LAMICTAL ODT |
| • |
LAMICTAL ODT is another form of LAMICTAL. |
| • |
Cases of life-threatening serious rashes, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and/or rash-related death, have been caused by LAMICTAL. The rate of serious rash is greater in pediatric patients than in adults. Additional factors that may increase the risk of rash include:
| – coadministration with valproate |
|
– exceeding recommended initial dose of LAMICTAL
|
|
– exceeding recommended dose escalation of LAMICTAL
|
|
| • |
Benign rashes are also caused by LAMICTAL; however, it is not possible to predict which rashes will prove to be serious or life-threatening. LAMICTAL should be discontinued at the first sign of rash, unless the rash is clearly not drug-related (see Boxed Warning in Prescribing Information). |
| • |
Hypersensitivity reaction may be fatal or life-threatening. Early signs of hypersensitivity (eg, fever, lymphadenopathy) may present without rash; if signs present, patient should be evaluated immediately. LAMICTAL should be discontinued if alternate etiology for hypersensitivity signs is not found. |
| • |
Prior to initiation of treatment with LAMICTAL, the patient should be instructed that a rash or other signs or symptoms of hypersensitivity (eg, fever, lymphadenopathy) may herald a serious medical event and that the patient should report any such occurrence to a physician immediately. |
| • |
Acute multiorgan failure has resulted (some cases fatal). |
| • |
Blood dyscrasias (eg, neutropenia, thrombocytopenia, pancytopenia) may result either with or without an associated hypersensitivity syndrome. |
| • |
Antiepileptic drugs, including LAMICTAL ODT, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. |
| • |
Patients treated with any antiepileptic drug for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. |
| • |
Patients, their caregivers, and families should be informed that antiepileptic drugs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.
|
Medication Guide for LAMICTAL® (lamotrigine) Tablets and LAMICTAL® ODT™ (lamotrigine) Orally Disintegrating Tablets |
Complete Prescribing Information and Medication Guide for LAMICTAL® (lamotrigine) Tablets and LAMICTAL® ODT™ (lamotrigine) Orally Disintegrating Tablets including Boxed Warning |
|
Important Safety Information
